CytoImmune Therapeutics, LLC

In 2017, the US Food and Drug Administration approved Novartis AG ’s Kymriah for the treatment of patients with acute lymphocytic leukaemia (ALL). The decision marked a sea change – Kymriah became th

In 2017, the US Food and Drug Administration approved Novartis AG ’s Kymriah for the treatment of patients with acute lymphocytic leukaemia (ALL). The decision marked a sea change – Kymriah became th

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Opts Not To Continue Leber Conge